Hypersensitivity to mycophenolate mofetil in systemic lupus erythematosus: diagnostic measures and successful desensitization

Int Arch Allergy Immunol. 2005 Dec;138(4):334-6. doi: 10.1159/000088873. Epub 2005 Oct 13.

Abstract

Despite therapeutic advances in the treatment of systemic lupus erythematosus (SLE), several patients are still afflicted with severe and uncontrolled symptoms. Recently, mycophenolate mofetil (MMF) has been introduced in the treatment of SLE, with a significant therapeutic benefit, and minor side effects have been reported. Data on the adverse effects of MMF in SLE are lacking. We present an SLE patient who developed urticaria during MMF treatment. Rechallenge with MMF established the diagnosis of MMF-induced urticaria. As MMF was considered a necessary therapy, a desensitization protocol was devised, which successfully induced tolerance to MMF. This is the first published protocol for MMF desensitization, which induced tolerance in an SLE patient previously reacting with generalized urticaria.

Publication types

  • Case Reports

MeSH terms

  • Desensitization, Immunologic / methods
  • Drug Hypersensitivity / etiology*
  • Drug Hypersensitivity / immunology
  • Drug Hypersensitivity / prevention & control
  • Female
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / immunology
  • Immunosuppressive Agents / therapeutic use
  • Lupus Erythematosus, Systemic / drug therapy*
  • Middle Aged
  • Mycophenolic Acid / adverse effects
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / immunology
  • Mycophenolic Acid / therapeutic use
  • Urticaria / chemically induced
  • Urticaria / immunology

Substances

  • Immunosuppressive Agents
  • Mycophenolic Acid